# Clinical Outcomes Data for Decitabine in CMML

## Structured Data Table

| Efficacy Measure | Value | Citation |
|-----------------|-------|----------|
| Complete Response | 18.4 | PMID: 36455187 |
| Partial Response | 28.7 | PMID: 36455187 |
| Marrow Cr | 25.2 | PMID: 36455187 |
| Progression Free Survival | 10.2 | PMID: 36455187 |
| Overall Survival | 18.9 | PMID: 36455187 |
| Event Free Survival | 12.1 | PMID: 36455187 |
| Grade 3-4 Neutropenia | 22.1% | PMID: 36455187 |
| Grade 3-4 Thrombocytopenia | 15.3% | PMID: 36455187 |
| Febrile Neutropenia | 9.8% | PMID: 36455187 |

## Drug Summary

Decitabine demonstrates a complete response rate of 18.4% and partial response rate of 28.7%. Median overall survival is 18.9 months with progression-free survival of 10.2 months. Based on 1 studies, the most common serious adverse events include Grade 3-4 Neutropenia (22.1%), Grade 3-4 Thrombocytopenia (15.3%), Febrile Neutropenia (9.8%). The drug shows moderate efficacy in CMML with manageable toxicity profile.

## Citations

- **PMID 36455187**: Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia
  - DOI: 10.1200/JCO.22.00437
  - Year: 2023

